Human Immunodeficiency Virus Therapeutics Market Size, Trends, Analysis, and Outlook By Drug (Branded Drugs, Generic Drugs), By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry and Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors, Coreceptor Antagonists), by Region, Country, Segment, and Companies, 2024-2030
The global Human Immunodeficiency Virus Therapeutics market size is poised to register 4.23% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Human Immunodeficiency Virus Therapeutics market across By Drug (Branded Drugs, Generic Drugs), By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry and Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors, Coreceptor Antagonists).
The human immunodeficiency virus (HIV) therapeutics market is experiencing significant growth, driven by advancements in antiretroviral therapy, increasing access to treatment, and efforts to combat the global HIV/AIDS epidemic. HIV is a chronic viral infection that attacks the immune system, leading to acquired immunodeficiency syndrome (AIDS) if left untreated. Antiretroviral therapy (ART) has revolutionized the management of HIV infection, enabling individuals living with HIV to achieve viral suppression, restore immune function, and lead long and healthy lives. Healthcare providers are utilizing a combination of antiretroviral drugs, including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors, and entry inhibitors, to suppress viral replication, prevent disease progression, and reduce the risk of HIV transmission. With a focus on early diagnosis, treatment initiation, and adherence support, infectious disease specialists, HIV/AIDS clinicians, and public health agencies are collaborating to scale up HIV testing and treatment programs, reach underserved populations, and achieve the global targets for ending the HIV/AIDS epidemic. Additionally, advancements in drug development, long-acting injectable therapies, and HIV cure research, along with expanding access to pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) regimens, are driving market expansion as stakeholders strive to address the evolving challenges of HIV/AIDS prevention, treatment, and care, and improve health outcomes for individuals affected by this complex and stigmatized infectious disease.
Human Immunodeficiency Virus Therapeutics Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Human Immunodeficiency Virus Therapeutics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Human Immunodeficiency Virus Therapeutics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Human Immunodeficiency Virus Therapeutics industry.
Key market trends defining the global Human Immunodeficiency Virus Therapeutics demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Human Immunodeficiency Virus Therapeutics Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Human Immunodeficiency Virus Therapeutics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Human Immunodeficiency Virus Therapeutics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Human Immunodeficiency Virus Therapeutics industry
Leading Human Immunodeficiency Virus Therapeutics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Human Immunodeficiency Virus Therapeutics companies.
Human Immunodeficiency Virus Therapeutics Market Study- Strategic Analysis Review
The Human Immunodeficiency Virus Therapeutics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Human Immunodeficiency Virus Therapeutics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Human Immunodeficiency Virus Therapeutics Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Human Immunodeficiency Virus Therapeutics Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Human Immunodeficiency Virus Therapeutics market segments. Similarly, Strong end-user demand is encouraging Canadian Human Immunodeficiency Virus Therapeutics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Human Immunodeficiency Virus Therapeutics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Human Immunodeficiency Virus Therapeutics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Human Immunodeficiency Virus Therapeutics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Human Immunodeficiency Virus Therapeutics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Human Immunodeficiency Virus Therapeutics Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Human Immunodeficiency Virus Therapeutics in Asia Pacific. In particular, China, India, and South East Asian Human Immunodeficiency Virus Therapeutics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Human Immunodeficiency Virus Therapeutics Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Human Immunodeficiency Virus Therapeutics Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Human Immunodeficiency Virus Therapeutics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Human Immunodeficiency Virus Therapeutics.
Human Immunodeficiency Virus Therapeutics Market Company Profiles
The global Human Immunodeficiency Virus Therapeutics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc, Genentech Inc, Gilead Sciences Inc, Merck & Co. Inc, ViiV Healthcare
Recent Human Immunodeficiency Virus Therapeutics Market Developments
The global Human Immunodeficiency Virus Therapeutics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Human Immunodeficiency Virus Therapeutics Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Geographical Segmentation:
AbbVie Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Inc
Genentech Inc
Gilead Sciences Inc
Merck & Co. Inc
ViiV Healthcare
Formats Available: Excel, PDF, and PPT
The human immunodeficiency virus (HIV) therapeutics market is experiencing significant growth, driven by advancements in antiretroviral therapy, increasing access to treatment, and efforts to combat the global HIV/AIDS epidemic. HIV is a chronic viral infection that attacks the immune system, leading to acquired immunodeficiency syndrome (AIDS) if left untreated. Antiretroviral therapy (ART) has revolutionized the management of HIV infection, enabling individuals living with HIV to achieve viral suppression, restore immune function, and lead long and healthy lives. Healthcare providers are utilizing a combination of antiretroviral drugs, including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors, and entry inhibitors, to suppress viral replication, prevent disease progression, and reduce the risk of HIV transmission. With a focus on early diagnosis, treatment initiation, and adherence support, infectious disease specialists, HIV/AIDS clinicians, and public health agencies are collaborating to scale up HIV testing and treatment programs, reach underserved populations, and achieve the global targets for ending the HIV/AIDS epidemic. Additionally, advancements in drug development, long-acting injectable therapies, and HIV cure research, along with expanding access to pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) regimens, are driving market expansion as stakeholders strive to address the evolving challenges of HIV/AIDS prevention, treatment, and care, and improve health outcomes for individuals affected by this complex and stigmatized infectious disease.
Human Immunodeficiency Virus Therapeutics Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Human Immunodeficiency Virus Therapeutics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Human Immunodeficiency Virus Therapeutics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Human Immunodeficiency Virus Therapeutics industry.
Key market trends defining the global Human Immunodeficiency Virus Therapeutics demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Human Immunodeficiency Virus Therapeutics Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Human Immunodeficiency Virus Therapeutics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Human Immunodeficiency Virus Therapeutics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Human Immunodeficiency Virus Therapeutics industry
Leading Human Immunodeficiency Virus Therapeutics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Human Immunodeficiency Virus Therapeutics companies.
Human Immunodeficiency Virus Therapeutics Market Study- Strategic Analysis Review
The Human Immunodeficiency Virus Therapeutics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Human Immunodeficiency Virus Therapeutics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Human Immunodeficiency Virus Therapeutics Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Human Immunodeficiency Virus Therapeutics Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Human Immunodeficiency Virus Therapeutics market segments. Similarly, Strong end-user demand is encouraging Canadian Human Immunodeficiency Virus Therapeutics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Human Immunodeficiency Virus Therapeutics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Human Immunodeficiency Virus Therapeutics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Human Immunodeficiency Virus Therapeutics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Human Immunodeficiency Virus Therapeutics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Human Immunodeficiency Virus Therapeutics Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Human Immunodeficiency Virus Therapeutics in Asia Pacific. In particular, China, India, and South East Asian Human Immunodeficiency Virus Therapeutics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Human Immunodeficiency Virus Therapeutics Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Human Immunodeficiency Virus Therapeutics Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Human Immunodeficiency Virus Therapeutics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Human Immunodeficiency Virus Therapeutics.
Human Immunodeficiency Virus Therapeutics Market Company Profiles
The global Human Immunodeficiency Virus Therapeutics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc, Genentech Inc, Gilead Sciences Inc, Merck & Co. Inc, ViiV Healthcare
Recent Human Immunodeficiency Virus Therapeutics Market Developments
The global Human Immunodeficiency Virus Therapeutics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Human Immunodeficiency Virus Therapeutics Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
AbbVie Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Inc
Genentech Inc
Gilead Sciences Inc
Merck & Co. Inc
ViiV Healthcare
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Human Immunodeficiency Virus Therapeutics Market Overview and Key Findings, 2024
1.2 Human Immunodeficiency Virus Therapeutics Market Size and Growth Outlook, 2021- 2030
1.3 Human Immunodeficiency Virus Therapeutics Market Growth Opportunities to 2030
1.4 Key Human Immunodeficiency Virus Therapeutics Market Trends and Challenges
1.4.1 Human Immunodeficiency Virus Therapeutics Market Drivers and Trends
1.4.2 Human Immunodeficiency Virus Therapeutics Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Human Immunodeficiency Virus Therapeutics Companies
2. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE OUTLOOK TO 2030
2.1 Human Immunodeficiency Virus Therapeutics Market Size Outlook, USD Million, 2021- 2030
2.2 Human Immunodeficiency Virus Therapeutics Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Human Immunodeficiency Virus Therapeutics Market, 2025
5.2 Asia Pacific Human Immunodeficiency Virus Therapeutics Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Human Immunodeficiency Virus Therapeutics Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Human Immunodeficiency Virus Therapeutics Market, 2025
5.5 Europe Human Immunodeficiency Virus Therapeutics Market Size Outlook by Type, 2021- 2030
5.6 Europe Human Immunodeficiency Virus Therapeutics Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Human Immunodeficiency Virus Therapeutics Market, 2025
5.8 North America Human Immunodeficiency Virus Therapeutics Market Size Outlook by Type, 2021- 2030
5.9 North America Human Immunodeficiency Virus Therapeutics Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Human Immunodeficiency Virus Therapeutics Market, 2025
5.11 South America Pacific Human Immunodeficiency Virus Therapeutics Market Size Outlook by Type, 2021- 2030
5.12 South America Human Immunodeficiency Virus Therapeutics Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Human Immunodeficiency Virus Therapeutics Market, 2025
5.14 Middle East Africa Human Immunodeficiency Virus Therapeutics Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Human Immunodeficiency Virus Therapeutics Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Human Immunodeficiency Virus Therapeutics Market Size Outlook and Revenue Growth Forecasts
6.2 US Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
7. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS COMPANY PROFILES
8.1 Profiles of Leading Human Immunodeficiency Virus Therapeutics Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
AbbVie Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Inc
Genentech Inc
Gilead Sciences Inc
Merck & Co. Inc
ViiV Healthcare
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Human Immunodeficiency Virus Therapeutics Market Overview and Key Findings, 2024
1.2 Human Immunodeficiency Virus Therapeutics Market Size and Growth Outlook, 2021- 2030
1.3 Human Immunodeficiency Virus Therapeutics Market Growth Opportunities to 2030
1.4 Key Human Immunodeficiency Virus Therapeutics Market Trends and Challenges
1.4.1 Human Immunodeficiency Virus Therapeutics Market Drivers and Trends
1.4.2 Human Immunodeficiency Virus Therapeutics Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Human Immunodeficiency Virus Therapeutics Companies
2. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE OUTLOOK TO 2030
2.1 Human Immunodeficiency Virus Therapeutics Market Size Outlook, USD Million, 2021- 2030
2.2 Human Immunodeficiency Virus Therapeutics Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Drug Type
Branded Drugs
Generic Drugs
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Human Immunodeficiency Virus Therapeutics Market, 2025
5.2 Asia Pacific Human Immunodeficiency Virus Therapeutics Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Human Immunodeficiency Virus Therapeutics Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Human Immunodeficiency Virus Therapeutics Market, 2025
5.5 Europe Human Immunodeficiency Virus Therapeutics Market Size Outlook by Type, 2021- 2030
5.6 Europe Human Immunodeficiency Virus Therapeutics Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Human Immunodeficiency Virus Therapeutics Market, 2025
5.8 North America Human Immunodeficiency Virus Therapeutics Market Size Outlook by Type, 2021- 2030
5.9 North America Human Immunodeficiency Virus Therapeutics Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Human Immunodeficiency Virus Therapeutics Market, 2025
5.11 South America Pacific Human Immunodeficiency Virus Therapeutics Market Size Outlook by Type, 2021- 2030
5.12 South America Human Immunodeficiency Virus Therapeutics Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Human Immunodeficiency Virus Therapeutics Market, 2025
5.14 Middle East Africa Human Immunodeficiency Virus Therapeutics Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Human Immunodeficiency Virus Therapeutics Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Human Immunodeficiency Virus Therapeutics Market Size Outlook and Revenue Growth Forecasts
6.2 US Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Human Immunodeficiency Virus Therapeutics Industry Drivers and Opportunities
7. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS COMPANY PROFILES
8.1 Profiles of Leading Human Immunodeficiency Virus Therapeutics Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
AbbVie Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Inc
Genentech Inc
Gilead Sciences Inc
Merck & Co. Inc
ViiV Healthcare
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
